Home › Compare › OSAGY vs ABBV
OSAGY yields 1.64% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, OSAGY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OSAGY + ABBV for your $10,000?
OSRAM Licht AG provides various lighting products and solutions worldwide. The company operates through three segments: Opto Semiconductors, Automotive, and Digital. It manufactures light-emitting diodes (LEDs) that are used in general lighting, automotive, consumer, and industrial applications; and infrared, laser, and optical sensors for the automotive, smartphone, wearable, general lighting, industrial lighting, and projection sectors, as well as lightings for plants. The company also develops and produces lamps and lighting systems for stages, cinemas, and studios; LED-based plant cultivation systems; lighting solutions for industrial and medical applications, such as high-intensity UV lamps and LED illumination for clothing; and automotive systems based on LED and laser technology, and other customer-specific system solutions. In addition, it develops, produces, and markets LED light engines and light management systems, as well as electronic ballasts, LED drivers, and LED modules. Further, the company is involved in the provision of products in the areas of architectural interior and exterior lighting, as well as professional interior lighting solutions. It provides its products under the OSRAM, Vixar, SYLVANIA, Traxon, e:cue, Digital Lumens, Fluence, Clay Paky, ADB Stagelight, OSRAM CONTINENTAL, LED Engin, and b,a,g, brands. The company was formerly known as Kyros A AG and changed its name to OSRAM Licht AG in November 2012. The company was founded in 1906 and is headquartered in Munich, Germany. OSRAM Licht AG operates as a subsidiary of ams AG.
Full OSAGY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.